Fulcrum Therapeutics (FULC) News Today $7.11 +0.08 (+1.14%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$7.10 0.00 (-0.07%) As of 06/5/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Mackenzie Financial Corp Has $555,000 Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Mackenzie Financial Corp boosted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 412.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 118,025 shares of the company's stock after acquiring an additional 94,997 shares durinJune 3 at 4:06 AM | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest UpdateFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 4,930,000 shares, a growth of 45.0% from the April 30th total of 3,400,000 shares. Currently, 9.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 553,400 shares, the short-interest ratio is presently 8.9 days.June 2, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 38,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Two Sigma Advisers LP lowered its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 10.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 343,600 shares of the company's stock after selling 38,600 shares during the period. Two SigmMay 31, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (FULC): A Bull Case TheoryMay 30, 2025 | msn.comFulcrum Therapeutics to Present at Upcoming Medical MeetingsMay 29, 2025 | globenewswire.comFulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 29, 2025 | globenewswire.comLeerink raises Fulcrum Therapeutics stock to OutperformMay 26, 2025 | uk.investing.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded by Leerink Partnrs to "Strong-Buy" RatingLeerink Partnrs upgraded Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday.May 26, 2025 | marketbeat.comWoodline Partners LP Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Woodline Partners LP grew its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 110.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,410,520 shares of the company's stock after acquirMay 26, 2025 | marketbeat.comNorthern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Northern Trust Corp raised its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 710,321 shares of the comMay 26, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded to Outperform at Leerink PartnersLeerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $4.00 to $12.00 in a research note on Friday.May 25, 2025 | marketbeat.comLeerink Partners Upgrades Fulcrum Therapeutics (FULC)May 23, 2025 | msn.comFulcrum gains as Leerink upgrades ahead of data for lead assetMay 23, 2025 | msn.comSherbrooke Park Advisers LLC Has $212,000 Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Sherbrooke Park Advisers LLC trimmed its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 80.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,157 shares of the company's stock after selliMay 23, 2025 | marketbeat.comFulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell TreatmentMay 23, 2025 | uk.investing.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. reduced its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 583,203 shares of the company's stockMay 22, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Suvretta Capital Management LLCSuvretta Capital Management LLC increased its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 182.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,338,466 shares of the company's stMay 19, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Graham Capital Management L.P.Graham Capital Management L.P. increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 58.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 144,942 shares of the company's stock after buying an additional 53,726 shares during theMay 17, 2025 | marketbeat.comCantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC)May 16, 2025 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of "Reduce" by AnalystsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus rating of "Reduce" from the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The averaMay 16, 2025 | marketbeat.comCAMP4 Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | nasdaq.comCisco upgraded, CoreWeave downgraded: Wall Street's top analyst callsMay 15, 2025 | finance.yahoo.comBridgeway Capital Management LLC Purchases New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Bridgeway Capital Management LLC acquired a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 140,000 shares of the company'May 14, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comFulcrum Therapeutics (FULC) Projected to Post Earnings on MondayFulcrum Therapeutics (NASDAQ:FULC) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-fulcrum-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results, Beats Estimates By $0.01 EPSFulcrum Therapeutics (NASDAQ:FULC - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01.May 5, 2025 | marketbeat.comBoothbay Fund Management LLC Reduces Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Boothbay Fund Management LLC lessened its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 60.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,533 shares of the company's stoMay 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases Shares of 213,213 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 213,213 shares of the company's stock,May 4, 2025 | marketbeat.comEarnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net lossMay 3, 2025 | uk.investing.comFulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comFulcrum therapeutics targets key data from PIONEER trial in Q3 2025May 2, 2025 | msn.comQ1 2025 Fulcrum Therapeutics Inc Earnings CallMay 2, 2025 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...May 2, 2025 | finance.yahoo.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025May 1, 2025 | globenewswire.com2FULC : Uncovering Potential: Fulcrum Therapeutics's Earnings PreviewApril 30, 2025 | benzinga.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. increased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 50.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,000,000 shares of the company's stock aftApril 30, 2025 | marketbeat.comFulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ETApril 24, 2025 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of "Hold" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned a consensus recommendation of "Hold" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hoApril 21, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Large Decrease in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 3,730,000 shares, a decrease of 28.5% from the March 15th total of 5,220,000 shares. Based on an average daily trading volume, of 448,900 shares, the days-to-cover ratio is presently 8.3 days. Currently, 7.2% of the shares of the company are short sold.April 20, 2025 | marketbeat.comAltium Capital Management LLC Buys Shares of 111,812 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Altium Capital Management LLC bought a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 111,812 shares of the company's stock, valued at approximatelApril 20, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Bought by ADAR1 Capital Management LLCADAR1 Capital Management LLC grew its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 177.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,248 shares of the company's stock after acquiring an aApril 9, 2025 | marketbeat.comNext-generation CRISPR company raises $68 million, zeroes in on first clinical trialMarch 27, 2025 | bizjournals.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from BrokeragesShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, sMarch 25, 2025 | marketbeat.comSimplify Asset Management Inc. Sells 270,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Simplify Asset Management Inc. trimmed its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 77.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,714 shares of the company's stock after selling 270,600 sMarch 24, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 176.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 367,594 shares of the company's stock after buying an additional 234,81March 20, 2025 | marketbeat.comBristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research DealMarch 5, 2025 | benzinga.comFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comHC Wainwright Issues Negative Estimate for FULC EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Fein now expects that the company will post earniMarch 1, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook for FULC Q1 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.35) per sMarch 1, 2025 | marketbeat.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.700.71▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼43▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JANX News Today ETNB News Today ADPT News Today DYN News Today SPRY News Today EVO News Today TVTX News Today ANIP News Today MESO News Today OCUL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump plotting new lockdown?It's listed inside the White House's own documents: Federal Register notice 90 FR 4544 to be exact. And wh...Porter & Company | SponsoredWhy hasn't Elon tweeted about this?Behind the scenes, there's an entirely different Tesla story brewing… . It's about a quiet stream of income...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
